lorazepam has been researched along with nortriptyline in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Babbini, M; Bartoletti, M; Gaiardi, M | 1 |
| Dunckley, HG; Schiff, AA; Sinclair, JM; Walsh, MR | 1 |
| Ritchie, JA; Truelove, SC | 1 |
| Fink, M | 1 |
| Begley, AE; Buysse, DJ; Frank, E; Houck, PR; Kupfer, DJ; Mazumdar, S; Perel, JM; Reynolds, CF | 1 |
| Datta, S; Tsen, LC | 1 |
3 review(s) available for lorazepam and nortriptyline
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for lorazepam and nortriptyline
| Article | Year |
|---|---|
A test of the concept of "underlying depressive illness" in the treatment of anxiety states.
Topics: Adjustment Disorders; Adult; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Drug Combinations; Female; Fluphenazine; Humans; Lorazepam; Male; Middle Aged; Nortriptyline | 1976 |
Comparison of various treatments for irritable bowel syndrome.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Colonic Diseases, Functional; Dietary Fiber; Drug Combinations; Drug Therapy, Combination; Female; Fluphenazine; Humans; Lorazepam; Male; Middle Aged; Nortriptyline; Phenethylamines; Random Allocation; Scopolamine | 1980 |
Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy?
Topics: Age Factors; Aged; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Electroencephalography; Female; Humans; Lorazepam; Male; Nortriptyline; Polysomnography; Psychiatric Status Rating Scales; Psychotherapy; Sleep | 1997 |
10 other study(ies) available for lorazepam and nortriptyline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Effects of combined treatment with nortriptiline and lorazepam on conflict behavior and motility of rats.
Topics: Animals; Anti-Anxiety Agents; Conditioning, Operant; Conflict, Psychological; Drug Interactions; Lorazepam; Male; Motor Activity; Nortriptyline; Punishment; Rats | 1976 |
Toxic serotonin syndrome or neuroleptic malignant syndrome?
Topics: Antidepressive Agents, Tricyclic; Central Nervous System Diseases; Electroconvulsive Therapy; Female; Humans; Lorazepam; Middle Aged; Neuroleptic Malignant Syndrome; Nortriptyline | 1996 |
Panic attacks and lactated Ringer's solution: is there a relationship?
Topics: Adult; Analgesia, Epidural; Anesthetics, Local; Diagnostic Errors; Female; Humans; Isotonic Solutions; Lorazepam; Nortriptyline; Obstetric Labor Complications; Panic Disorder; Postpartum Period; Pregnancy; Ringer's Lactate | 1999 |